Patients
Trials
Expanded Access
Pipeline
Zanidatamab
ZW49
Preclinical & Advanced Discovery
Partnerships
Publications
Partners
Technology
Azymetric™
ZymeLink™
EFECT™
ProTECT™
Science
Careers
Apply
Perks & Benefits
Corporate Gallery
About
Leadership
Board of Directors
News
Investors & Media
News
Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
Nov 09, 2021
Back